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The coreceptor usage of HIV-1 envelope proteins (Env) is mainly dependent on a defined variable region within the V3-loop of Env. Thus,
retroviral vectors derived from murine leukemia virus (MLV), which have been pseudotyped with HIV-1 envelope proteins holding different V3-
loops, enable selective gene delivery into either CXCR4 or CCR5 positive cultured cells. Here, we tested the distribution of CD4/CCR5-tropic
[MLV(HIV)]-pseudotype vectors in transgenic mice expressing CD4 and either CXCR4 or CCR5 of human origin. The specificity of gene transfer
was analyzed by ex vivo transduction of spleen cells as well as after i.v. or i.p. injection of transgenic mice. Expression of the transferred marker
gene EGFP and vector sequences could be detected exclusively in lymphocytes expressing (hu)CD4 and (hu)CCR5, whereas MLV vectors
pseudotyped with the VSV-G envelope glycoprotein mediated gene transfer in mice of all genotypes investigated. These data demonstrated that
cell-specific gene delivery via [MLV(HIV)]-pseudotyped vectors, as previously shown for cultured cells, is also achievable in vivo.
© 2006 Elsevier Inc. All rights reserved.Keywords: HIV coreceptor usage; Retroviral pseudotype vectors; In vivo distributionIntroduction
Cell type-specific in vivo gene delivery is one favorable
goal in gene therapy. However, basic concerns are the
undesirable transduction of many, not disease-related cell
types and the fear of germ-line transmission following in
vivo administration of viral vectors (Connolly, 2002; Smith,
2003), in particular if vectors are used that can integrate into
the genome. Accordingly, up to now, mainly non-integrating
vectors such as adenoviral vectors have been used for in vivo
gene delivery in clinical trials, whereas in vivo application of
retroviral vectors will require efficient targeting of specific
cell populations.⁎ Corresponding author. Fax: +49 6103 771255.
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doi:10.1016/j.virol.2006.03.034The host range of retroviruses is mainly determined by
the surface (SU) domain of the envelope (Env) glycoprotein,
which mediates binding to the surface receptor (Bartosch
and Cosset, 2004; Haynes et al., 2003). Accordingly, besides
others, various strategies to target retroviral vectors were
based on modification of the viral Env protein. For example,
retroviral gene transfer into specific cell types has been
attempted by inserting antibody fragments or other targeting
ligands into the ecotropic Env glycoprotein of Moloney
murine leukemia virus (MoMLV), so far with only limited
success (Schnierle et al., 1996; Benedict et al., 1999; Gollan
and Green, 2002; Bartosch and Cosset, 2004). Providing
retroviral vector particles with adapter antibodies resulted in
significant reduction of vector titers (Kasahara et al., 1994;
Valsesia-Wittmann et al., 1994; Haynes et al., 2003). As a
general rule, modified Env proteins can show specific
binding properties; however, they often suffer from low
fusion activity, which in turn, leads to inefficient transduc-
tion of target cells (Zhao et al., 1999). Other targeting
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MoMLV Env protein. This prevents infection, unless the
blocking domains are cleaved off by proteases. In one such
example, matrix-metalloproteases that are predominantly
secreted by tumor cells cleaved off a blocking domain,
thus enabling selective targeting of tumor cells (Chowdhury
et al., 2004; Hartl et al., 2005). Finally, retroviruses are
readily amenable to replacement of their Env proteins by
those of other viruses, whereby the cell specificity is deter-
mined by the foreign envelope. Such so-called retroviral
pseudotype vectors have been generated using for example
the Env glycoproteins of human hepatitis B virus, Sendai
virus, Gibbon ape leukemia virus, or vesicular stomatitis virus t
(Sung and Lai, 2002; Spiegel et al., 1998; Wilson et al., 1998;
Burns et al., 1993). In most cases, specific tropism of modified
vectors has been satisfactorily shown in cell culture experi-
ments only, whereas reports on efficient in vivo targeting are
rare (Jiang and Dornburg, 1999; Martin et al., 2002; Morizono
et al., 2005).
In line with the targeting approach to use heterologous
Env proteins, we and others described that MLV particles
can be pseudotyped with a C-terminally truncated variant of
a (hu)CD4/(hu)CXCR4-tropic HIV-1 Env glycoprotein
(Schnierle et al., 1997; Mammano et al., 1997; Stitz et al.,
2000). Thus, the Env glycoprotein conferred the natural
tropism of HIV-1 to the [MLV(HIV)] vector particle, which
was then shown to specifically transduce human CD4/
CXCR4-positive cells. To enable usage of the CCR5
coreceptor as well, the V3-loop of the truncated HIV-1
Env protein was replaced by that of a CCR5-tropic HIV-1
strain to generate a CD4/CCR5-specific [MLV(HIV)] vector.
The coreceptor specificity of the resulting CCR5- or
CXCR4-tropic pseudotype vector has been verified by in
vitro transduction of cultured cell lines expressing CD4 and
one of the aforementioned coreceptors (Stitz et al., 1998).
Coreceptor switch could also be demonstrated by analogous
replacement of the V3-loop of the Env protein of a simian
immunodeficiency virus used for pseudotyping of MLV
vectors (Steidl et al., 2002). These developments might pave
the way for gene therapy protocols focusing on targeting T
lymphocytes which are involved not only in inherited
diseases such as adenosine desaminase deficiency (ADA)
and severe combined immunodeficiency disease (SCID), but
also in acquired diseases like acquired immune deficiency
syndrome (AIDS) or cancer, e.g., cutaneous T cell
lymphomas (CTCLs). For example, Thaler et al. (2003)
successfully used [MLV(HIV)]-pseudotype vector particles to
transfer a suicide gene for specific transduction of a human
T cell lymphoma xenograft in a mouse model resulting in
reduction of tumor growth.
In the present study, we investigated the tropism of
[MLV(HIV)]-pseudotype vectors in transgenic animal mod-
els. Vectors were administered i.v. or i.p. into mice
harboring cells which expressed various combinations of
human CD4 and CXCR4 or CCR5. Our data demonstrated
that [MLV(HIV)] vectors allowed a strictly cell type-specific
gene transfer in vivo.Results
Generation of CCR5- or CXCR4-tropic [MLV(HIV)]
pseudotype vectors
[MLV(HIV)]-vectors were produced by use of stable
packaging cell lines expressing MLV gag/pol, a packaging
signal-positive EGFP-carrying MLV transfer vector, and
either a CCR5-tropic or a CXCR4-tropic HIV-1-derived env
gene. The stable packaging cell line K52SR20 harbors the
CXCR4-tropic env gene of HIV-1 BH10 (Stitz et al., 1998),
and the cell clone MBK.15 contains the CCR5-tropic env
gene of the same strain modified by replacing the V3-loop
by that of CCR5-tropic HIV-1 strain MBK (Steidl et al.,
2002). Vectors were harvested from cell culture supernatants,
and specificity for CD4 and coreceptors was confirmed by
transduction of GHOST-CCR5 and GHOST-CXCR4 cell
lines expressing the respective receptors (Cecilia et al.,
1998) as described (Steidl et al., 2002). Usually, titers of
5×105 transducing units per ml (TU/ml) or 1×106 TU/ml
were obtained for the CXCR4- or the CCR5-tropic vector,
respectively, which could be concentrated up to 3-fold by
ultracentrifugation.
Transgenic mouse models used for in vivo and ex vivo targeting
studies
For investigation of cell-specific gene delivery by [MLV
(HIV)]-pseudotype vector particles, we used the mouse
strains B6CBAF⁎C57BL/6 [Tg](hu)CD4/(hu)CCR5 or
B6CBAF⁎C57BL/6 [Tg](hu)CD4/(hu)CXCR4 that were
double transgenic for the human CD4 in combination with
one of the human coreceptors, CCR5 or CXCR4 (LaCasse
et al., 1999). To prove the genotype of each individual
mouse, surface expression of transgene products was
checked by FACS analysis of peripheral blood mononuclear
cells (PBMCs) (Fig. 1A), whereas genotypes were con-
firmed by PCR analysis (Fig. 1B). Since the transgenic
mice used carried heterozygous transgenes, besides double
transgenic mice, single transgenics expressing only (hu)
CD4, (hu)CXCR4, or (hu)CCR5 were also obtained during
breeding.
Receptor-specific ex vivo gene transfer into lymphocytes of
transgenic mice
To analyze the ability of CD4/CXCR4- and CD4/CCR5-
tropic [MLV(HIV)] vector particles to transduce cells from
transgenic mice, we treated spleen lymphocyte suspensions ex
vivo. To this end, lymphocytes were isolated by Ficoll gradient
from spleens of transgenic mice expressing the combinations of
the transgenes as indicated. The splenic lymphocytes typically
consisted of about 55% CD3+ T cells and 45% CD19+ B cells
as determined by FACS analysis (data not shown). Subsequent-
ly, cells were stimulated for 2 days with α-CD3 and α-CD28
antibodies, and successful activation of lymphocytes was
monitored by analysis of CD69 and CD86 upregulation (data
Fig. 1. Confirmation of genotypes of transgenic animals. (A) Surface expression of human CD4, CCR5, or CXCR4 on PBMCs from transgenic mice. PBMCs from
mice of each genotype, as indicated on top, were analyzed by two-color FACS analysis for (hu)CD4 and either (hu)CCR5 (left panel) or (hu)CXCR4 (right panel) using
the conjugated antibodies indicated. The percentage of positive cells in each quadrant is indicated. (B) PCR detection of transgenes from transgenic animals. PCR
products after amplification of DNA frommice of the genotype indicated on top using primer pairs specific for human CD4, CCR5, or CXCR4 as indicated to the right.
β-Actin primers were used as an internal control.
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with CCR5- or CXCR4-tropic [MLV(HIV)] vectors at a
multiplicity of infection (MOI) of 0.2–0.4. Six days after
transduction, lymphocytes were analyzed by FACS for
expression of the marker gene EGFP and the human HIV
receptors (Fig. 2). As expected, only cells positive for both
(hu)CD4 and (hu)CCR5 could be transduced by the CD4/
CCR5-tropic [MLV(HIV)] vectors (Fig. 2A, upper panel),
and only cells positive for (hu)CD4 and (hu)CXCR4 could
be transduced by the CD4/CXCR4-tropic vectors (Fig. 2A,
lower panel). The occurrence of EGFP-expressing CCR5-
negative cells after transduction with the CD4/CCR5-tropic
vector is probably due to downregulation of CCR5 during
lymphocyte cultivation after transduction as described
previously (Mengozzi et al., 2001; Brandt et al., 2002)
rather than to transduction of CCR5-negative cells.
In three independent experiments, transduction rates were
about 10%. In contrast, gene transfer was not detectable in
lymphocytes expressing in addition to (hu)CD4 the inappro-
priate coreceptor, or in lymphocytes expressing only one of the
transgenic receptors (Fig. 2B). In summary, we demonstrated
specific coreceptor usage of CD4/CCR5- and CD4/CXCR4-
tropic [MLV(HIV)] vector particles in primary murine lympho-
cytes in ex vivo experiments.Receptor specificity of CD4/CCR5-tropic [MLV(HIV)] vectors
in vivo
Transgenic mice expressing (hu)CXCR4 showed a disturbed
CD4 T cell homeostasis (Sawada et al., 1998). Furthermore,
usage of the murine CXCR4 by CXCR4-tropic HIV Env has
been described (Bieniasz et al., 1997; Mitnacht-Kraus and
Schnierle, 2002). Therefore, we decided to omit analysis of
CXCR4-tropic vector in vivo and focussed on analysis of
CCR5-tropic vectors.
Since MLV-derived vectors can transduce only dividing
cells, lymphocytes were activated in vivo 1 day prior to vector
application by i.p. administration of 100 μg keyhole limpet
hemocyanin (KLH). Twenty-four hours later, FACS analysis of
peripheral CD4+ cells revealed an increased percentage of
CD86-positive T cells of about 16% in comparison to about 6%
in naïve mice. In the peritoneal cavity of non-treated mice,
about 40% of the lymphocytes were CD86-positive a priori, but
this proportion was not increased after KLH stimulation (data
not shown).
At first, gene transfer was investigated after i.v. administra-
tion of vectors using non-transgenic mice, (hu)CD4, (hu)CCR5,
or (hu)CXCR4 single transgenic mice, or (hu)CD4/(hu)CXCR4
or (hu)CD4/(hu)CCR5 double transgenic mice (2 animals per
Fig. 2. Ex vivo transduction of murine spleen mononuclear cells from transgenic
animals using [MLV(HIV)] vectors. Proof of gene transfer by detection of EGFP
and HIV receptor expression. (A) Representative three-color FACS analysis of
spleen lymphocytes from (hu)CD4/(hu)CCR5 (upper panel) or (hu)CD4/(hu)
CXCR4 mice (lower panel) after transduction with CCR5- or CXCR4-tropic
[MLV(HIV)] vectors, respectively. EGFP-expressing cells (gates R2 or R4 of the
left panels) are re-analyzed for expression of HIV receptor and coreceptor (right
panels). The percentage of positive cells in each quadrant is indicated. (B)
Synopsis of the results obtained after transduction of cells from mice of all
genotypes using both vectors. −: no gene transfer. +: gene transfer proven by
EGFP expression.
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vector particles were applied to each mouse by three injections
at 24, 32, and 48 h after KLH treatment. Five days later, the
animals were sacrificed and the gene transfer was analyzed by
fluorescent microscopy and FACS analysis of EGFP expression
in lymphocytes from peripheral blood, spleen, or peritoneal
cavity, as well as by PCR analysis of vector sequences in spleen,
liver, thymus, and bone marrow. Gene transfer was demon-
strated exclusively in (hu)CD4/(hu)CCR5 double-transgenic
mice by detection of sporadic EGFP-expressing splenic
lymphocytes by fluorescent microscopy (data not shown).
Vector-specific DNAwas also detected in the spleen and liver of
(hu)CD4/(hu)CCR5 double-transgenic mice (Fig. 5B), but not
in the spleen and liver of other animals. Peripheral bloodlymphocytes did not show EGFP expression. Therefore,
although low transduction frequencies were observed, the
gene transfer detected exclusively in animals of the respective
genotype confirmed the specificity of the CD4/CCR5-tropic
[MLV(HIV)] vector for cells expressing (hu)CD4/(hu)CCR5.
Next, transduction experiments were performed using the
i.p. injection route. In each of four independent experiments,
two animals per genotype were investigated. A total of
8×106 infectious CCR5-tropic [MLV(HIV)] vector particles
were administered to each mouse by repeated i.p. injection
24, 32, 48, and 56 h after KLH treatment, and the animals
were analyzed as described above. Again, gene transfer
could be detected by fluorescent microscopy (Fig. 3) and by
FACS analysis (Fig. 4) exclusively in (hu)CD4/(hu)CCR5
double-transgenic mice, but not in (hu)CD4, (hu)CCR5, or
(hu)CXCR4 single transgenic or (hu)CD4/(hu)CXCR4 dou-
ble transgenic mice. The efficiency of transduction was
significantly higher than after i.v. application: in (hu)CD4/
(hu)CCR5 transgenic mice, about 0.15% of lymphoid cells
from the peritoneal cavity were found to express EGFP (Fig.
4B), which correspond to about 0.3% of all (hu)CD4/(hu)
CCR5 positive target cells (Fig. 4C). Remarkably, positive
cells were sporadically also found in spleen but not in
peripheral blood by fluorescence microscopy (not shown).
Within the lymphoid cells from the peritoneal cavity, about
90% of all EGFP-expressing cells were (hu)CD4 and (hu)
CCR5 positive (Fig. 4B), indicating the selectivity of the
[MLV(HIV)] vector also in in vivo experiments. The
presence of about 8% EGFP-positive cells expressing only
(hu)CCR5 but not (hu)CD4 may rather be due to loss of
(hu)CD4 expression after transduction of double-positive
cells than to transduction of (hu)CCR5 positive/(hu)CD4-
negative cells, since no EGFP-expressing cells were detected
in (hu)CCR5 single transgenic mice (Fig. 4D) indicating the
need for receptor and coreceptor for transduction.
By PCR analysis, vector sequences were detected in spleen
(Fig. 5A) and, albeit to a lower extent, in thymus and liver of
(hu)CD4/(hu)CCR5 double transgenic mice. Again, vector
DNA amplification was negative using organs of mice of all
other genotypes, even if a second round of PCR was performed.
A summary of the PCR results obtained from two independent
PCR assays for each mouse and tissue upon i.v. or i.p.
administration of the vector is shown in Fig. 5B.
As a positive control, MLV vectors pseudotyped with the
glycoprotein of the vesicular stomatitis virus (VSV-G),
which is known to mediate receptor-independent transduc-
tion of a high number of target cells from different species
(Mastromarino et al., 1987; Tatsuo et al., 2000), were
administered i.p. as described above for [MLV(HIV)] vectors
to (hu)CCR5/(hu)CD4-, (hu)CD4/(hu)CXCR4- transgenic,
and wild type mice (4 animals per group). EGFP expression
was detected in lymphocytes from spleen and peritoneal
cavity (Fig. 3) of all mice investigated, indicating that
transduction worked independently of (hu)CD4 and core-
ceptor expression. Furthermore, vector sequences were
detected by PCR in cells isolated from spleen, bone marrow
(Figs. 5A and B), liver, and thymus (Fig. 5B), from mice of
Fig. 3. In vivo transduction of transgenic mice. Fluorescence microscopy of lymphocytes from the abdominal cavity of mice of the genotypes indicated 5 days after i.p.
application of [MLV(HIV-CCR5)] or [MLV(VSV-G)] vectors as indicated. Left panel: Fluorescence image. Right panel: Bright field superimposed with fluorescence
image. Appearance of lymphocytes from (hu)CD4, (hu)CCR5, or (hu)CXCR4 single transgenic mice transduced with [MLV(HIV-CCR5)] vectors was identical to
those of wild type mice (not shown).
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in principle susceptible for transduction with MLV-derived
vectors.
Taken together, these data demonstrate that [MLV(HIV)]
vectors have the ability to mediate coreceptor-specific gene
transfer to CD4 positive target cells in vivo, depending on the
particular envelope used for pseudotyping. Gene transfer wasmore efficient when the vector particles were administered i.p.
than i.v.
Discussion
The development of targeted vectors is crucial for many in
vivo approaches in human gene therapy. The ultimate goal
Fig. 4. Expression of HIV receptors and EGFP in peritoneal lymphocytes from transgenic mice after i.p. application of [MLV(HIV-CCR5)] vectors. FACS analysis of
representative mice. Peritoneal lymphocytes from a (hu)CD4/(hu)CCR5 double-transgenic mouse (A) were analyzed for EGFP expression followed by re-analysis of
positive cells for (hu)CD4 and (hu)CCR5 (B), or were primarily analyzed for presence of (hu)CD4 and (hu)CCR5 followed by analysis of double-positive cells for
EGFP expression (C). The percentage of positive cells in relevant sections is given. (D) EGFP expression in peritoneal lymphocytes from wild type (wt), single
transgenic (hu)CD4 or (hu)CCR5 mice as indicated.
242 S. Schüle et al. / Virology 351 (2006) 237–247would be the systemic delivery of gene transfer vectors that may
include the possibility for repeated administration. With respect
to safety issues related to ectopic transgene expression and
chromosomal vector integration, it is essential that these vectors
are highly specific for transduction of selected target cell types.
In this regard, we and others previously described pseudotyping
of MoMLV particles with the Env glycoprotein of HIV-1, which
then displayed in vitro the natural tropism of HIV-1 to CD4-
positive human cells (Schnierle et al., 1997; Mammano et al.,
1997; Stitz et al., 2000). These vectors are probably the most
efficient cell type-specific vectors generated by pseudotyping
(Haynes et al., 2003). Thaler et al. (2003) reported selective
transduction of human CD4 cancer cells by such vectors in a
murine xenograft model. The present report demonstrates for
the first time the tropism of [MLV(HIV)] vectors upon i.v. and i.
p. injection in transgenic mice. In particular, in vivo
administration of vectors pseudotyped with HIV-1 envelopes
specific for CD4/CCR5 proved the need for the (hu)CCR5
coreceptor in addition to (hu)CD4 for transduction.It has previously been reported that the murine variant of
CXCR4 is a functional coreceptor for CXCR4-tropic [MLV
(HIV)] vectors after transfection of mammalian cells with (hu)
CD4 and (mu)CXCR4 (Bieniasz et al., 1997). Also endogenous
CXCR4 present in the murine cell line TA3 expressing human
(hu)CD4 is able to mediate HIV-1 infection (Mitnacht-Kraus
and Schnierle, 2002). In contrast, our data on the ex vivo
transduction of primary lymphocytes isolated from spleens of
transgenic mice suggested the requirement for the respective
human coreceptors in addition to the human CD4 receptor (Fig.
2B). However, in accordance to the data of Schabath et al.
(1999), we found that only 11% of murine splenocytes were
positive for murine CXCR4 in non-transgenic mice as well as in
all transgenic mouse strains investigated. Accordingly, since
about 30% of the splenocytes were (hu)CD4-positive, only
about 3% of splenocytes from (hu)CD4-transgenic mice were
found double-positive for both, human CD4 and murine
CXCR4. Moreover, the expression level of murine CXCR4 in
single transgenic murine splenocytes was significantly lower
Fig. 5. Detection of gene transfer by PCR amplification of EGFP sequences in organs from transduced mice. (A) Amplification products obtained from spleen (upper
panel) or bone marrow (lower panel) of mice of the genotypes indicated on top after transduction with CCR5-tropic [MLV(HIV)] or [MLV(VSV-G)] vectors as
indicated. β-Actin primers were used as an internal control. (B) Summary of PCR analysis of organs from transgenic mice transduced in vivo (either i.v. or i.p.) with
CCR5-tropic [MLV(HIV)] or [MLV(VSV-G)] vectors. Results are given as the rates of positives/total number of mice tested.
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FACS analysis (data not shown). Thus, absence of ex vivo
transduction of splenocytes from (hu)CD4 single transgenic
mice via the endogenous murine CXCR4 coreceptor may be
due to low murine CXCR4 expression as already suggested by
Sawada et al. (1998).
Further on, Sawada et al. (1998) reported that expression of
(hu)CXCR4 in lymphocytes of transgenic mice resulted in a
disturbed CD4 T cell homeostasis in vivo, whereas transgenic
mice expressing (hu)CCR5 did not reveal any abnormalities of
the hematopoietic system (Keppler et al., 2002). This was
confirmed by our data, since only about 3% of the lymphocytes
from the peripheral blood but about 30% of the spleenlymphocytes of CXCR4-transgenic mice were found to be
(hu)CD4-positive, whereas in (hu)CCR5-transgenic mice about
30% of the lymphocytes were CD4-positive both in the
peripheral blood as well as in the spleen (data not shown).
Therefore, to avoid confusing results due to possible usage of
murine CXCR4 as coreceptor, as well as to the disturbed CD4
homeostasis in (hu)CXCR4 transgenic mice, we focused our in
vivo analysis on properties of the CCR5-tropic [MLV(HIV)]
vector.
The clear-cur result on the in vivo transduction capacity of
this vector exclusively for lymphocytes of mice transgenic for
both (hu)CD4 and (hu)CCR5 was further confirmed by the
analysis of EGFP-expressing cells, that were positive for both
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G-pseudotyped MLV vectors proved that also wt and (hu)CD4/
(hu)CXCR4-transgenic mice were permissive for transduction
with MLV vectors, thus verifying that the in vivo specificity of
the CCR5-tropic vector observed was indeed due to receptor
and coreceptor expression.
The efficiency of transduction of cells from the appropriate
mouse strains was comparable with previous results. Ex vivo
transduction efficiencies for lymphocytes were similar for the
CCR5-tropic and the CXCR4-tropic vector and was about 10%
when an m.o.i. of 0.2–0.4 was used, which was in the range as
described for human peripheral blood lymphocytes in similar
approaches (Indraccolo et al., 1998; Stitz et al., 1998; Thaler
and Schnierle, 2001). In vivo, gene transfer rates were very low
when vectors were administrated i.v. Only sporadic EGFP-
expressing cells could be detected in the spleen, and
amplification of vector DNA from other organs was only
successful in some of the animals. In previous reports on higher
transduction rates after i.v. application, significant higher vector
titers up to 1010 were used (Follenzi et al., 2002; Pan et al.,
2002) which was not possible in our study due to the limited
titers of the [MLV(HIV)] vectors generated. Still, i.p.
administration resulted in about 0.15% EGFP-expressing
peritoneal lymphocytes detectable by fluorescence microscopy
or FACS analysis when 8×106 TU were used. This was in the
same range as already described for a comparable rat model
under similar conditions (Keppler et al., 2002). In that report,
the authors administered i.p. 9×106 infectious units of a
replication-competent HIV-1 strain, resulting in 0.15% infected
lymphocytes detected by EGFP expression. The lack of vector
sequences detectable by PCR in other organs of some of the
mice confirmed the predominance of vectors in lymphocytes of
the peritoneal cavity. Thus, although the low gene transfer rates
of the vectors investigated are far from those necessary for in
vivo gene therapy approaches, they reflect the current capacity
of such vectors and are sufficient to accomplish the goal of our
study which was the in vivo examination of target cell
specificity.
The reason for the higher transduction rates after i.p. in
comparison to i.v. administration of CD4/CCR5-tropic [MLV
(HIV)] vectors remains unclear. It can be speculated that
following i.v. application, the vector particles are rapidly
disseminated within the blood circuit and may contact and
stick to a variety of blood cells or to the endothelium, thus
becoming unavailable for transduction of target cells. Never-
theless, negative selection of transduced lymphocytes induced
by the transduction process cannot be excluded, for example
due to modulation of lymphocyte activation and homing.
Within the peritoneal cavity, the retention period of vector
particles is expected to be significantly higher due to lower
circulation rates. Accordingly, EGFP-expressing lymphocytes
could be detected in the peritoneal cavity, but not in the
peripheral blood. Transduced lymphocytes detected after i.p.
injection in the spleen and vector sequences detected in thymus
and liver may reflect lymphocyte migration from the peritoneal
cavity (Luettig et al., 2001), or accumulation of peripheral
lymphocytes after i.v. application. The higher efficiency of i.padministration may be attributable to the higher dosage
achievable due to the higher volume which could be
administered i.p., or the higher activation level of lymphocytes
as proven by evaluation of activation markers.
In conclusion, we have shown that the coreceptor-specificity
of HIVenvelopes determined by the V3-loop of Env previously
demonstrated in cell culture experiments is also preserved in
vivo. Thus, a coreceptor-specific in vivo gene transfer into
CD4-positive cells is possible, emphasizing the suitability of
[MLV(HIV)]-pseudotyped vectors as valuable tools for gene
therapy approaches targeting T lymphocytes. However, our
results underline problems of systemic i.v. application of viral
vectors such as the needs for high titer vectors for in vivo gene
delivery.
Materials and methods
Cell culture
The human kidney cell line 293T (ATCC CRL-11268), the
TELCeB6-derived (Cosset et al., 1995) packaging clones
K52SR20 (Stitz et al., 1998) and MBK.15 (Steidl et al.,
2002), as well as the human osteosarcoma cell lines GHOST-
CCR5 and GHOST-CXCR4 (Cecilia et al., 1998), kindly
provided by Dr. M. Dittmar (DKFZ, Heidelberg, Germany),
were grown in Dulbecco's modified Eagle's medium (DMEM)
supplemented with 10% heat-inactivated FCS (Seromed,
Biochrom KG, Berlin, Germany), 100 U/ml streptomycin/
penicillin, and 2 mM L-glutamine.
The stable packaging clones K52SR20, harboring the
CXCR4-tropic env gene of HIV-1 BH10 (Stitz et al., 1998),
and the cell clone MBK.15, harboring the CCR5-tropic env
gene of HIV-1 BH10 modified by inserting the V3-loop of
MBK (Steidl et al., 2002), were permanently cultured in the
presence of 5 μg/ml blasticidine S (ICN; Biochemicals, Logan,
UT), 800 μg/ml G418 (Gibco/Life Technologies, Eggenstein,
Germany), and 4.5 g/l glucose. The CXCR4- or CCR5-carrying
GHOST cells were maintained under antibiotic selection in the
presence of 100 μg/ml hygromycin (Gibco/Life Technologies),
500 μg/ml G418 (Gibco/Life technologies), and 1 μg/ml
puromycin (ICN, Biochemicals).
Vector production, concentration, and titration
For [MLV(HIV)] vector production, the packaging clones
K52SR20 and MBK.15 were cultured in 10-stack cell factories
(Nunc, Wiesbaden, Germany) until they reached confluence. To
increase vector production, the culture medium was removed
16 h before harvesting and exchanged with 500 ml medium
containing 6 mM sodium butyrate (BIOMOL, Hamburg,
Germany). VSV-G pseudotyped MLV-vectors were produced
by transient transfection, 1.8×107 cells were seeded on T175
culture flasks 24 h before gene transfer. Cells were transfected
with 18 μg of the retroviral transfer vector pMgEGFP-
▵LNGFR, which codes for EGFP (Clontech, Palo Alto, CA)
and truncated low-affinity human nerve growth factor receptor
(▵LNGFR) which are expressed under the control of a murine
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pHIT60 (Soneoka et al., 1995), and 3.5 μg of the VSV-G
envelope construct pMD.G (Naldini et al., 1996) using
LipofectAMINE Plus, according to the manufacturer's instruc-
tions (GIBCO/Life Technologies). One day after transfection,
the medium was replaced by fresh medium and vector
containing supernatant was harvested 24 h after medium
exchange.
In general, collected supernatants were filtered through
0.45 μm filters and concentrated by ultracentrifugation
(25.000 rpm for 2 h at 4 °C in a Sorval SW28 rotor) in aliquots
of 30 ml of cell culture supernatant through 20% sucrose in
PBS. Subsequently supernatants were removed and the vector
pellets resolved in 200 μl PBS. Concentrated supernatants were
stored at −80 °C.
Vector titers were determined by serial dilution of [MLV
(HIV)] supernatants on the respective GHOST cell line and of
VSV-G pseudotyped vectors on 293T cells. The number of
EGFP-expressing cells was detected 4 days after transduction
by FACS analysis and titers were determined by calculating the
percentage of EGFP-positive cells.
Animal model
B6CBAF⁎C57BL/6 mice, transgenic for (hu)CD4/(hu)
CXCR4 or (hu)CD4/(hu)CCR5 (LaCasse et al., 1999), were
obtained from Taconic Farms, Inc. (Germantown, NY) and
housed in a pathogen-free facility. The offspring was
screened for transgene expression by FACS analysis of
blood cells. All mice were 6 to 12 weeks of age, and a
minimum of 2 mice per experimental group were used in all
experiments. Mice were i.p. treated with 100 μg KLH
(Keyhole Limpet Hemocyanin) and the following day vector
stock was injected i.v. (200 μl) at 24, 32, and 48 h or i.p.
(1 ml) at 24, 32, 48, and 56 h. On day 5 after transduction,
blood was taken and mice were sacrificed to collect organs.
Peritoneal lavage was performed by flooding the peritoneal
cavity with 5 ml PBS. All animal experiments were in
accordance with the German Animal License Regulations
(Tierschutzgesetz).
Isolation and transduction of primary mouse cells
Spleen mononuclear cells (SMCs) were prepared by passing
minced spleen through a nylon cell strainer and cells were
purified by Ficoll Histopaque (density 1.083 g/ml) density
gradient centrifugation (Sigma, St. Louis, USA). Cells were
maintained in standard RPMI 1640 medium (including 10%
heat-inactivated FCS, 100 U/ml streptomycin/penicillin, 2 mM
L-glutamine) which was additionally supplemented with 1 mM
Sodium Pyruvate (Gibco/Life Technologies), 100 μM NEAA
(Non Essential Amino Acids, Gibco/Life Technologies), and
50 μM β-Mercaptoethanol (Gibco/Life Technologies). For
activation, 3.5×106 SMCs/ml were cultured for 2 days in anti-
CD3 (10 μg/ml PBS) precoated 6-well dish and 100 μl anti-
CD28 (0.1 μg/ml) was added. For transduction, 2×106 SMCs/
ml were seeded into 24-well plates, and 300 μl of vectorcontaining supernatant, IL-2 (100 U/ml), and proteamine sulfate
(4 μg/ml) were added. Subsequently, cells were centrifuged for
1 h at 300×g and 31 °C, and medium was exchanged after 6 h.
Transduced cells were cultivated for additional 6 days before
analysis of transgene expression.
Flow cytometry
Whole blood FACS analysis was performed from heparin-
treated blood samples using the DAKO Uti-Lyse kit (DAKO
Corporation, Carpinteria, USA) according to the manufacturer's
protocol. Lymphocyte samples were incubated for 30 min with
monoclonal antibodies α(hu)CCR5-PE, α(hu)CXCR4-PE,
α(hu)CD4-PerCP-Cy5, α(mu)CD3-FITC, α(mu)CD69-PE,
and α(mu)CD86-PE obtained from BD Bioscience (Heidelberg,
Germany) or α(mu)CD19-PE, α(mu)CD8-PE, and α(mu)CD4-
PE obtained from DAKO (DAKO Corporation). EGFP
expression was analyzed in the green fluorescence channel
(FL-1). Samples were analyzed with a FACScan cytometer (BD
Bioscience) using Cellquest software.
PCR of vector sequences from genomic DNA
Genomic DNA from different tissues and cells was isolated
using the DNeasy Tissue Kit (Qiagen, Hilden, Germany)
according to the manufacturer's instructions. PCR amplification
for human CD4 and CCR5 from transgenic mice was done by
standard PCR using primers as follows: (hu)CD4 (forward): 5′
TGG GGC CAC AGA CTC ACA 3′; (reverse) 5′ GGC CTT
CAT CCC TGC TCG TAA A 3′, (hu)CCR5 (forward): 5′ CTG
GCCATC TCTGACCTG TTT TTC 3′; (reverse) 5′CAGCCC
TGT GCC TCT TCT TCT CAT and (hu)CXCR4 (forward) 5′
GAA ATG GGC TCA GGG GAC TAT G 3′; (reverse) 5′ CCT
TGG CCT CTG ACT GTT GGT G 3′. Detection of egfp-
sequences was performed by standard PCR using 1 μg of
genomic DNA, whereby 1/3 of the first round of PCR
amplification was used for a second round of PCR. A 373 bp
fragment was amplified, using primers as follows: EGFP
(forward): 5′ CGTCCAGGAGCGCACCATCTTCTT 3′ and
(reverse) 5′ ATCGCGCTTCTCGTTGGGGTCTTT 3′. As
internal control, a 390 bp-fragment of the human gene β-actin
was amplified. As positive control, the respective plasmid
(pMG.egfp/Δlngfr) was used.
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